AEGLEA BIOTHERAPEUTICS, INC.
901 S. MoPac Expressway
Barton Oaks Plaza One, Suite 250
Austin, TX 78746
May 25, 2017
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Suzanne Hayes |
| Assistant Director |
| Office of Healthcare and Insurance |
| Re: | Aeglea BioTherapeutics, Inc. |
| Registration Statement on Form S-3 |
| Filed May 1, 2017 |
| File No. 333-217573 |
Via EDGAR - Acceleration Request
| Requested Date: | May 30, 2017 |
| Requested Time: | 4:30 p.m. Eastern Time |
Ladies and Gentlemen:
Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Effie Toshav, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| AEGLEA BIOTHERAPEUTICS, INC. | ||
| By: | /s/ Charles N. York II | |
| Charles N. York II | ||
| Chief Financial Officer | ||
| cc: | David G. Lowe, Chief Executive Officer |
| Aeglea BioTherapeutics, Inc. |
| Robert A. Freedman, Esq. |
| Effie Toshav, Esq. |
| Fenwick & West LLP |